Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa
Executive Summary
Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22
You may also be interested in...
Will Three Be The Charm For FDA Review Of Antipsychotics For Pediatric Use?
FDA’s Psychopharmacologic Drugs Advisory Committee will evaluate pediatric indications for AstraZeneca’s Seroquel, Pfizer’s Geodon and Lilly’s Zyprexa during its June 9-10 meeting.
Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity
J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA
Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity
J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA